Evidence map›Paper›PMID 32212799›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2020

IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.

Yasser H ElNahass, Ragia H Badawy, Fatma A ElRefaey, Hend A Nooh, Dalia Ibrahiem, Heba A Nader, Hossam K Mahmoud, Wafaa H ElMetnawy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yasser H ElNahassNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Ragia H BadawyNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Fatma A ElRefaeyNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Hend A NoohNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Dalia IbrahiemNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Heba A NaderGenome Onco-Center, 52, Gameat Al Dowal Alarabya , Mohandeseen, Cairo, Egypt.
Hossam K MahmoudNational Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt.
Wafaa H ElMetnawyFaculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, Egypt.
National Water Research Center · EGAl-Azhar University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIDH mutations diversely affect the prognosis of cyogenetically normal acute myeloid leukemia (CN-AML) adult patients. The aim of this study is to assess the frequency of IDH mutations and to evaluate its role in AML prognosis.

methodsWe have analyzed IDH1 and 2 mutations using High Resolution Melting curve analysis (HRM) in 70 denovo AML patients.

resultsThe median age of AML patients is 40 years (16-75). Incidence of IDH mutations is 10/70 (14.3%); 2 (2.9%) IDH1 mutant and 8 (11.4%) IDH2 mutant. Median PB blasts of mutant IDH patients was 67.5% (25-96) vs. 44% (0-98) for wild type (p=0.065). Eight/10 (80%) mutant IDH patients had B.M blasts ≥50% vs. 2/10 (20%) <50% (p<0.001) and were classified as intermediate risk cytogenetics (p=0.020) with wild FLT3-ITD (p=0.001). Ten/10 (100%) mutant IDH patients showed wild NPM1 (p=0.049). Median OS of mutant IDH in the intermediate risk cytogenetics was 1.8 years (0.7-3.1) vs. 3.1 years (1.1-5.5) for wild IDH (p=0.05).

conclusionIDH mutation is mainly associated with intermediate risk AML and when integrated in this specific subgroup displays a lower survival and can be considered an additional integrated molecular risk marker for AML prognosis.<br />.

Indexed as

MutationAdolescentAdultAgedFemaleHumansIsocitrate DehydrogenaseKaryotypingLeukemia, Myeloid, AcuteMaleMiddle AgedNucleophosminRisk FactorsYoung AdultIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseNPM1 protein, humanNucleophosminAMLIDH mutationsintermediate cytogenetic risknormal karyotypePrognosis

Identifiers

PMID32212799
PMCPMC7437334
OpenAlexW3013057567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.